Related Experiment Video
Updated: May 24, 2026

In Vitro Modeling of Cancerous Neural Invasion: The Dorsal Root Ganglion Model
Published on: April 12, 2016
Neuropilin-2 expression in cancer
Adrian M Jubb1, Susan M Sa, Navneet Ratti
1Department of Pathology, Genentech Inc., South San Francisco, CA 94080, USA. adrianj@gene.com
Neuropilin-2 is expressed in blood and lymphatic vessels across various cancers. Its tumor cell expression varies, impacting anti-neuropilin-2 therapy effectiveness in lung, breast, and colorectal cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metastasis
Background:
- Neuropilin-2 (NRP2) acts as a coreceptor for vascular endothelial growth factor (VEGF) family members.
- Blocking NRP2 has shown potential in suppressing lymphogenous metastasis in preclinical cancer models.
Purpose of the Study:
- To validate an in situ protocol for evaluating neuropilin-2 protein expression.
- To compare in situ protein expression with in situ hybridization, western blotting, and mRNA levels.
Main Methods:
- Immunohistochemistry was performed on normal human tissues and 79 primary non-small-cell lung carcinomas, 65 primary breast carcinomas, 79 primary colorectal cancers, and 52 metastases.
- Neuropilin-2 expression was also assessed in 55 primary and 9 secondary malignant melanomas using in situ hybridization.
Main Results:
- Neuropilin-2 expression was detected in the vasculature of all normal and malignant tissues examined.
- Tumor cell expression of neuropilin-2 was observed in 32% of non-small-cell lung cancers, 15% of breast cancers, and 22% of colorectal cancers.
- In malignant melanomas, 85% of primary tumors showed tumor cell expression of neuropilin-2.
Conclusions:
- Anti-neuropilin-2 therapies are likely to primarily target the vasculature in most lung, breast, and colorectal cancers.
- These findings aid in pharmacokinetic and tolerability assessments for anti-neuropilin-2 therapies.
- The results help guide the optimal clinical setting for evaluating anti-neuropilin-2 drug activity.
Related Concept Videos
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
